Vilanterol

[1]Slack RJ, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344 (1) :218-30|[2]Kempsford R, et al. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26 (2) :256-|[3]Harrell AW, et al. Metabolism and disposition of Vilanterol, a long-acting β (2) -adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41 (1) :89-100.|[4]Calzetta L, et al. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Jul 14. pii: S0014-2999 (17) 30470-3.|[5]Panayiotis A Procopiou, et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010 Jun 10. 53 (11) :4522-30.

Eur J Pharmacol. 2017 Oct 5:812:147-154.|J Neuroimmunol. 2019 Jul 15:332:37-48.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|Mental Health and Neuroscience Institute. University of Alberta. 2016 Sep.|University of Alberta. 2016.